REFERENCE
Lenalidomide: risk of thrombosis and thromboembolism. Drug Safety Update 4: A3, No. 7, Feb 2011
Omalizumab: potential risk of arterial thrombotic events. Drug Safety Update 4: A4, No. 7, Feb 2011
Rights and permissions
About this article
Cite this article
Lenalidomide and omalizumab linked to thrombotic events. React. Wkly. 1339, 1 (2011). https://doi.org/10.2165/00128415-201113390-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201113390-00001